Company Overview of BIND Therapeutics, Inc.
BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company, develops various targeted and programmable therapeutics. It is developing Accurins that are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. The company’s lead Accurin drug candidate includes BIND-014, a prostate-specific membrane antigen targeted Accurin that contains docetaxel and is in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. It has collaboration agreements to develop Accur...
325 Vassar Street
Cambridge, MA 02139
Founded in 2006
Key Executives for BIND Therapeutics, Inc.
Chief Executive Officer
Total Annual Compensation: $395.0K
Total Annual Compensation: $247.9K
Compensation as of Fiscal Year 2013.
BIND Therapeutics, Inc. Key Developments
Bind Therapeutics Announces New Clinical Trials Would Begin in Several Cancer Types
Jan 9 15
Bind Therapeutics announced that new clinical trials would begin in several cancer types. Clinical trials for the company's targeted therapy drug, a nanoparticle whose surface selectively binds with tumor cells, recently ended for lung cancer and prostate cancer, but the company announced that it would begin another set of clinical trials for lung cancer, based on promising results from the most recently concluded Phase 2 trial. Though the company has dropped prostate cancer research for now, Bind said it will also begin clinical trials on a number of other cancers, based on promising results from Phase 1 clinical trials. The second trial, which will include cervical cancer, head and neck cancer, bladder cancer and cholangiocarcinoma, or bile duct cancer, will begin enrolling patients in the next two months. Bind said there will be at least 20 patients per tumor type enrolled in the trial, with the possibility of the company expanding the trial to include more patients based on the results. Progress has also been made in the manufacturing of three different therapies with well-known partners. In addition, BIND has also begun formulation efforts with Merck, and said they have had positive results from initial formulation with AstraZeneca. The company expects one of its collaboration partners to file an FDA application for the nanoparticle therapy by mid-2015.
BIND Therapeutics, Inc. Provides Clinical Update for BIND-014
Jan 7 15
BIND Therapeutics, Inc. announced enrollment of the first patient expressing a KRAS mutation in a global, multicenter two-tiered phase 2 trial with BIND-014 in non-small cell lung cancer (NSCLC) patients with KRAS mutant tumors (mutated Kirsten ras oncogene homolog) or squamous histology. The trial was driven by positive results from the phase 2 trial in NSCLC presented at the EORTC-NCI-AACR Annual Symposium in Barcelona on November 19, 2014, with a confirmed objective response rate of 22%(n=9); one KRAS mutant NSCLC PR was also seen in the phase 1 trial with BIND-014, yielding a combined total response rate of 30%(n=10). Results from the phase 2 trial also suggested meaningful differentiation in NSCLC patients with squamous histology when compared to historical docetaxel results. BIND-014 results presented at EORTC-NCI-AACR also demonstrated a disease control rate of 66% and overall survival of 11.1 months (n=9) in NSCLC patients with squamous histology. BIND intends to begin accruing NSCLC patients with squamous cell histology in the two-tier phase 2 trial in first quarter of 2015. The company also announced topline data from its ongoing phase 2 trial with BIND-014 in metastatic castration resistant prostate cancer (mCRPC). The primary endpoint of the study was to determine the efficacy of BIND-014 as measured by radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve metastatic CRPC. The trial enrolled 42 patients, 31 of whom had been treated with androgen inhibitors prior to enrolling in the study. As of December 15, 2014, BIND-014 demonstrated a median rPFS of 8.1 months with three patients currently on treatment and 60% of the patients enrolled attained a rPFS of 6 months or greater. Safety and tolerability were also promising, with notable reductions in adverse effects that often limit dosing of conventional docetaxel, including hematologic and non-hematologic toxicities. As of December 15, 2014, three patients continue on treatment and 24 patients continue to be followed for overall survival. Complete results of the mCPRC trial will be presented at an upcoming medical meeting.
BIND Therapeutics, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 02:20 PM
Dec 3 14
BIND Therapeutics, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 02:20 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Speakers: Dan Koerwer, Senior Vice President of Business Development & Commercial.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|